Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against StubHub Holdings, Inc. due to allegations of misleading information in the company's registration statement during its IPO on September 17, 2025 [2][4]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in StubHub to contact them for discussing legal options [1]. - The firm is reminding investors of the January 23, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against StubHub [2]. Allegations Against StubHub - The class action complaint alleges that the registration statement was materially false and/or misleading, failing to disclose significant adverse facts about the company's business and operations [4]. - Specific undisclosed issues included changes in payment timing to vendors, which adversely affected free cash flow, leading to misleading reports [4]. Financial Performance - StubHub's IPO priced at $23.50 per share, with approximately 34 million shares sold [4]. - Following the release of third-quarter financial results on November 13, 2025, the company reported a free cash flow of negative $4.6 million, a 143% decrease from the previous year's positive $10.6 million [5]. - The company's net cash provided by operating activities was reported at $3.8 million, a 69.3% decrease from $12.4 million in the prior year [5][6]. Stock Price Impact - After the negative financial news, StubHub's stock price fell by $3.95 per share, or 20.9%, closing at $14.87 on November 14, 2025 [7]. - By the time of the legal action, the stock was trading as low as $10.31 per share, representing a nearly 56% decline from the IPO price [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Stride, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - The Class Period for the Stride securities is from October 22, 2024, to October 28, 2025, and the lead plaintiff deadline is January 12, 2026 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its success in this area [3] Group 3: Allegations Against Stride, Inc. - The lawsuit alleges that Stride made misleading statements regarding its products and services, inflating enrollment numbers and cutting staff costs beyond statutory limits [4] - The firm claims that these actions led to damages for investors when the true situation was revealed [4]

Core Viewpoint - Rosen Law Firm is urging investors of Cepton, Inc. to secure legal counsel before the December 8, 2025 deadline related to a securities class action lawsuit concerning misleading statements made by the company during the class period from July 29, 2024, to January 6, 2025 [1][5]. Group 1: Legal Action Details - Investors who purchased or sold Cepton common stock during the specified class period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 8, 2025 deadline to serve as lead plaintiff, which involves directing the litigation on behalf of other class members [3][6]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its leadership in securities class action settlements, being ranked No. 1 in 2017 and consistently in the top 4 since 2013 [4]. Group 3: Allegations Against Cepton, Inc. - The lawsuit alleges that Cepton's management made materially false and misleading statements regarding the company's business and operations, including failing to disclose a credible third-party bid that valued Cepton at more than double the Koito Acquisition [5]. - It is claimed that the Board of Directors did not adequately explore this offer or disclose its terms, depriving shareholders of the opportunity to make an informed decision regarding the Koito Acquisition [5].

Core Viewpoint - Rosen Law Firm is reminding purchasers of WPP plc American Depositary Shares (ADS) about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during a specified period [1][5]. Group 1: Class Action Details - The class period for the lawsuit is from February 27, 2025, to July 8, 2025, and the lead plaintiff deadline is December 8, 2025 [1]. - Investors who purchased WPP ADSs during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Allegations Against WPP - The complaint alleges that WPP provided overly positive statements while concealing material adverse facts about its media arm, which was not adequately equipped to handle macroeconomic challenges and was losing market share [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Primo Brands Corporation due to alleged violations of federal securities laws related to misleading statements about the merger with BlueTriton Brands and its integration process [2][5]. Group 1: Allegations and Impact - The complaint alleges that Primo Brands and its executives made false and misleading statements regarding the merger, leading investors to believe it would enhance growth and operational efficiencies [5]. - Issues began to surface on August 7, 2025, when Primo Brands reported Q2 2025 earnings, revealing disruptions in product supply and service due to the merger [5]. - Following the August 7 disclosure, the stock price fell by $2.41, approximately 9%, from $26.41 to $24.00 [5]. - On November 6, 2025, the company significantly reduced its full-year 2025 net sales and adjusted EBITDA guidance, and announced the replacement of CEO Rietbroek [6]. - New CEO Eric Foss acknowledged that the company had moved "too far too fast" with integration efforts, resulting in various operational issues [6]. Group 2: Stock Performance - After the November 6 disclosure, the stock price dropped by $8.20, or 36%, over the next two trading sessions, falling from $22.66 to $14.46 [7]. Group 3: Legal Proceedings - Investors who suffered losses during the specified class period are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][2]. - The deadline to seek the role of lead plaintiff in the federal securities class action against Primo Brands is January 12, 2026 [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status by December 8, 2025 [1][3]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false or misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [3]. - Specific allegations include a multi-year accounting scheme involving off-balance-sheet entities, fictitious transactions, and misleading disclosures to hide losses and inflate profits, with examples such as a $17 million fabricated receivable and nearly $1 billion in concealed derivatives exposure [4]. - Following the release of a damaging report, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 on heavy trading volume [5]. Group 2: Legal Proceedings and Investor Actions - The lead plaintiff in the class action will be the investor with the largest financial interest who is adequate and typical of class members, and any member of the class may move to serve as lead plaintiff [6]. - Faruqi & Faruqi encourages individuals with information regarding Marex's conduct, including whistleblowers and former employees, to come forward [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against James Hardie Industries plc due to allegations of misleading investors regarding the performance of its North America Fiber Cement segment between May 20 and August 18, 2025 [3]. Group 1: Allegations and Financial Impact - The complaint alleges that James Hardie and its executives violated federal securities laws by making false statements and failing to disclose that the company misled investors about the strength of its key segment, despite knowing about inventory destocking by distributors [3]. - On August 19, 2025, James Hardie reported a 29% decline in first-quarter profit and projected lower-than-expected fiscal 2026 earnings, attributing this to high borrowing costs [3]. - Following the announcement, the price of James Hardie's American Depositary Receipt (ADR) fell by $9.79, or 34.44%, closing at $18.64 on August 20, 2025 [4]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased securities in James Hardie between May 20, 2025, and August 18, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights, with a deadline of December 23, 2025, to seek the role of lead plaintiff in the class action [1][3]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5]. - Faruqi & Faruqi also invites anyone with information regarding James Hardie's conduct, including whistleblowers and former employees, to come forward [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and failure to disclose critical information regarding its prostate cancer therapeutic candidates, leading to significant investor losses [3][4][5]. Group 1: Allegations and Legal Actions - The complaint alleges that Telix and its executives materially overstated the progress of their prostate cancer therapeutic candidates and the quality of their supply chain, resulting in misleading statements about the company's business and prospects [3]. - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, which caused the price of Telix's American Depositary Shares to drop by over 13% in two trading sessions [4]. - Following the disclosure of a Complete Response Letter from the FDA on August 28, 2025, regarding deficiencies in the Chemistry, Manufacturing, and Controls package for TLX250-CDx, Telix's ADS price fell by more than 21% over two trading sessions [5]. Group 2: Class Action Details - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Telix is January 9, 2026, with the lead plaintiff being the investor with the largest financial interest who is typical of class members [6]. - Faruqi & Faruqi encourages anyone with information regarding Telix's conduct, including whistleblowers and former employees, to contact the firm [6].

Core Viewpoint - Inspire Medical Systems is facing legal scrutiny due to allegations of misleading investors regarding the demand and launch of its Inspire V device, leading to significant financial losses for investors [3][4][5]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical and has set a deadline of January 5, 2026, for investors to seek the role of lead plaintiff in a federal securities class action [1][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [2]. Group 2: Financial Impact - On August 4, 2025, Inspire Medical announced delays in the launch of the Inspire V device due to training and onboarding issues at treatment centers, as well as billing challenges with Medicare [4]. - Following the announcement of these setbacks, Inspire Medical's stock price plummeted over 32%, from $129.95 to $87.91 per share, resulting in a loss of approximately $1.2 billion in market capitalization [5]. - The company also reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [5].

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADS” or “ADSs”) of WPP plc (NYSE: WPP) between February 27, 2025 and July 8, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased WPP ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr ...